Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

161
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
161
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

136
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
136
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

522
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
522
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognosis biomarkers in MOGAD: What can we learn from observational studies?

Revue neurologique·2026
Same author

Criteria for the use of plasmapheresesis in optic neuritis: A practice review from French expert centers.

Revue neurologique·2025
Same author

French guidelines for the diagnosis and management of MOG antibody-associated disease.

Revue neurologique·2025
Same author

French protocol for the diagnosis and management of hematopoietic stem cell transplantation in autoimmune diseases.

La Revue de medecine interne·2024
Same author

Training first-year medical residents to break bad news using healthcare role-play and trainees as simulated patients: Experience of the "ADIAMED" program from Lille University School of Medicine.

La Revue de medecine interne·2023
Same author

Evaluation of a self-questionnaire to screen for neurological complications associated with immunological checkpoint inhibitors: Are we missing something?

Revue neurologique·2023

Related Experiment Video

Updated: Jun 28, 2025

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
09:41

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography

Published on: January 20, 2023

1.8K

Anti-CD20 monoclonal antibodies in multiple sclerosis: Rethinking the current treatment strategy.

S A Freeman1, H Zéphir2

  • 1Department of Neurology, CRC-SEP, CHU of Toulouse, Toulouse, France; University Toulouse III, Inserm UMR1291, CHU Purpan, Toulouse Institute for Infectious and Inflammatory Diseases (INFINITY), 59000 Toulouse, France.

Revue Neurologique
|April 10, 2024
PubMed
Summary

Anti-CD20 monoclonal antibodies are effective for multiple sclerosis (MS) but cause immunosuppression. Readapting these therapies with extended dosing intervals may reduce risks, but further research is needed.

Keywords:
Anti-CD20 therapiesExtended dosingMultiple sclerosisOcrelizumabRituximabSafety

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.2K
Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

816

Related Experiment Videos

Last Updated: Jun 28, 2025

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
09:41

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography

Published on: January 20, 2023

1.8K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.2K
Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

816

Area of Science:

  • Immunology
  • Neurology
  • Pharmacology

Background:

  • Anti-CD20 monoclonal antibodies are key B-cell depleting therapies for multiple sclerosis (MS).
  • These treatments significantly impact MS pathophysiology and disease course.
  • Current limitations include immunosuppression, infection risks, diminished vaccine response, and hypogammaglobulinemia.

Purpose of the Study:

  • To review available anti-CD20 therapies for MS.
  • To explore the potential of tailored dosing strategies.
  • To assess the impact of modified dosing on treatment-related risks.

Main Methods:

  • Review of current literature on anti-CD20 therapies in MS.
  • Analysis of data regarding extended dosing intervals.
  • Evaluation of risks associated with immunosuppression and hypogammaglobulinemia.

Main Results:

  • Extended dosing intervals show promise in maintaining inflammatory MS control.
  • The impact of tailored CD20 therapies on reducing hypogammaglobulinemia and infections remains under investigation.
  • Encouraging data suggests potential benefits of optimizing anti-CD20 therapy regimens.

Conclusions:

  • Tailoring anti-CD20 monoclonal antibody therapies is a potential next step in MS treatment.
  • Further investigation is required to confirm the benefits of modified dosing on reducing adverse outcomes.
  • Optimizing treatment strategies may mitigate long-term immunosuppression risks.